TGFBR1 and colorectal carcinoma: These results suggest combined inhibition of cell-specific signaling nodes such as myeloid PI3Kγ, lymphocyte PD-1, and mesenchymal TGF-βR1 could provide a powerful way to treat CRC as an interconnected heterocellular system.